⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Study of Leuprolide to Treat Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of Leuprolide to Treat Prostate Cancer

Official Title: A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations, in Subjects With Prostatic Adenocarcinoma

Study ID: NCT00626431

Conditions

Prostate Cancer

Study Description

Brief Summary: To assess the efficacy and safety of 2 new formulations of leuprolide acetate 45 mg 6-month depot, Formulation A or Formulation B, for the treatment of patients with prostate cancer. A formulation will be deemed successful if the percentage of subjects with suppression of testosterone to \<= 50 ng/dL from Week 4 to Week 48 is not less than 87%, (the lower bound of the 2-sided 90% confidence interval), a protocol-specified criterion.

Detailed Description: A total of 300 male subjects were planned to be enrolled. Subjects were to receive a total of 2 intramuscular (IM) injections of the same formulation, either Formulation A or Formulation B, administered 24 weeks apart. The first 150 subjects were to receive Formulation A for both injections and the next 150 subjects were to receive Formulation B for both injections. The sponsor was to conduct an ongoing review of the primary endpoint data (suppression of testosterone \<= 50 ng/dL) and planned to stop enrollment of Formulation A or Formulation B, or not to administer the second injection of Formulation A or Formulation B, if 15 or more subjects did not achieve testosterone suppression by Week 4 or failed to maintain testosterone suppression during the treatment period. All analyses and summaries were to be conducted separately for subjects who received Formulation A or Formulation B. This study was to be conducted at approximately 60-80 investigative sites. Subjects participated in the trial for approximately 14 months. This trial was to include a Screening Period (up to 4 weeks), a 12-month Treatment Period (two 6-month treatment cycles), and a Follow-Up Period (30 days).

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

Site Reference ID/Investigator# 8696, Birmingham, Alabama, United States

Site Reference ID/Investigator# 8681, Homewood, Alabama, United States

Site Reference ID/Investigator# 8569, Anchorage, Alaska, United States

Site Reference ID/Investigator# 9709, Phoenix, Arizona, United States

Site Reference ID/Investigator# 8662, Sierra Vista, Arizona, United States

Site Reference ID/Investigator# 8656, Tucson, Arizona, United States

Site Reference ID/Investigator# 9705, Little Rock, Arkansas, United States

Site Reference ID/Investigator# 8691, Anaheim, California, United States

Site Reference ID/Investigator# 8566, Atherton, California, United States

Site Reference ID/Investigator# 8686, Fresno, California, United States

Site Reference ID/Investigator# 8698, Laguna Hills, California, United States

Site Reference ID/Investigator# 9703, Long Beach, California, United States

Site Reference ID/Investigator# 8674, Los Angeles, California, United States

Site Reference ID/Investigator# 8650, Tarzana, California, United States

Site Reference ID/Investigator# 8699, Torrance, California, United States

Site Reference ID/Investigator# 8668, Denver, Colorado, United States

Site Reference ID/Investigator# 8646, Englewood, Colorado, United States

Site Reference ID/Investigator# 8652, Middlebury, Connecticut, United States

Site Reference ID/Investigator# 8697, New Britain, Connecticut, United States

Site Reference ID/Investigator# 8655, Aventura, Florida, United States

Site Reference ID/Investigator# 8648, Daytona Beach, Florida, United States

Site Reference ID/Investigator# 8660, New Smyrna Beach, Florida, United States

Site Reference ID/Investigator# 8658, Orange City, Florida, United States

Site Reference ID/Investigator# 8664, Orlando, Florida, United States

Site Reference ID/Investigator# 8651, Saint Augustine, Florida, United States

Site Reference ID/Investigator# 8661, St. Petersburg, Florida, United States

Site Reference ID/Investigator# 8568, Tallahassee, Florida, United States

Site Reference ID/Investigator# 8679, Wellington, Florida, United States

Site Reference ID/Investigator# 8562, West Palm Beach, Florida, United States

Site Reference ID/Investigator# 8670, Roswell, Georgia, United States

Site Reference ID/Investigator# 9708, Thomasville, Georgia, United States

Site Reference ID/Investigator# 8693, Fort Wayne, Indiana, United States

Site Reference ID/Investigator# 8690, Newburgh, Indiana, United States

Site Reference ID/Investigator# 8565, Overland Park, Kansas, United States

Site Reference ID/Investigator# 8676, Greenbelt, Maryland, United States

Site Reference ID/Investigator# 8653, Las Vegas, Nevada, United States

Site Reference ID/Investigator# 8667, Lawrenceville, New Jersey, United States

Site Reference ID/Investigator# 9702, Bronx, New York, United States

Site Reference ID/Investigator# 8665, New York, New York, United States

Site Reference ID/Investigator# 8657, Poughkeepsie, New York, United States

Site Reference ID/Investigator# 8680, Charlotte, North Carolina, United States

Site Reference ID/Investigator# 8673, Concord, North Carolina, United States

Site Reference ID/Investigator# 8666, Raleigh, North Carolina, United States

Site Reference ID/Investigator# 8570, Salisbury, North Carolina, United States

Site Reference ID/Investigator# 8644, Winston-Salem, North Carolina, United States

Site Reference ID/Investigator# 8663, Cincinnati, Ohio, United States

Site Reference ID/Investigator# 8567, Columbus, Ohio, United States

Site Reference ID/Investigator# 8678, Bethany, Oklahoma, United States

Site Reference ID/Investigator# 8563, Bala Cynwyd, Pennsylvania, United States

Site Reference ID/Investigator# 8692, Lancaster, Pennsylvania, United States

Site Reference ID/Investigator# 8689, Myrtle Beach, South Carolina, United States

Site Reference ID/Investigator# 8643, Germantown, Tennessee, United States

Site Reference ID/Investigator# 8695, Germantown, Tennessee, United States

Site Reference ID/Investigator# 8685, Memphis, Tennessee, United States

Site Reference ID/Investigator# 8564, Nashville, Tennessee, United States

Site Reference ID/Investigator# 8645, Nashville, Tennessee, United States

Site Reference ID/Investigator# 8641, Dallas, Texas, United States

Site Reference ID/Investigator# 8675, Houston, Texas, United States

Site Reference ID/Investigator# 8684, San Antonio, Texas, United States

Site Reference ID/Investigator# 8649, Tyler, Texas, United States

Site Reference ID/Investigator# 8683, Salt Lake City, Utah, United States

Site Reference ID/Investigator# 8672, Norfolk, Virginia, United States

Site Reference ID/Investigator# 8669, Richmond, Virginia, United States

Contact Details

Name: Kristof Chwalisz, MD, PhD

Affiliation: Abbott

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: